Big Day for Ajax Therapeutics with 2 big announcements

Ajax Therapeutics shared on X/Twitter:

“Big Day for Ajax Therapeutics with 2 big announcements! Number 1: We have closed our series C which gives us the resources to take our lead molecule to the clinic!

Ajax Announcement #2. The IND for our lead molecule, AJ-101095, a potent selective type II JAK inhibitor, has been cleared by the FDA. Next stop->clinic. Let’s go!.”

Source: Ajax Therapeutics/X and Ajax Therapeutics/X